| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | SIII; TCEB3; TCEB3A; SIII p110 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ELOA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ELOA(Elongin A)抗体的3篇模拟参考文献示例(内容为虚构，仅供参考)：
1. **文献名称**：*Structural Insights into ELOA Complexes in Transcriptional Regulation*
**作者**：Chen L, Smith JA, et al.
**摘要**：该研究通过冷冻电镜解析了ELOA与Elongin B/C复合物的三维结构，揭示了其在RNA聚合酶II介导的转录延伸中的调控机制，为开发靶向ELOA的抗体提供结构基础。
2. **文献名称**：*ELOA Expression Correlates with Tumor Progression in Colorectal Cancer*
**作者**：Wang Y, Tanaka K, et al.
**摘要**：通过免疫组化分析发现，ELOA在结直肠癌组织中高表达，且与患者生存率负相关。研究利用特异性ELOA抗体证实其可作为潜在肿瘤标志物。
3. **文献名称**：*Autoantibodies Against ELOA in Systemic Lupus Erythematosus*
**作者**：Gupta R, Martinez F, et al.
**摘要**：首次报道系统性红斑狼疮(SLE)患者血清中存在抗ELOA自身抗体，并通过ELISA和蛋白质印迹验证其特异性，提示ELOA可能参与自身免疫反应通路。
4. **文献名称**：*Development of a High-Affinity Monoclonal Antibody Targeting ELOA for Therapeutic Applications*
**作者**：Kim S, Park H, et al.
**摘要**：研究团队开发了一种新型抗ELOA单克隆抗体，体外实验显示其可抑制癌细胞增殖，并在小鼠模型中显著减少肿瘤生长，为靶向治疗提供新策略。
---
注：以上文献及内容为示例性虚构，实际引用请通过PubMed或专业数据库(如Web of Science)检索真实论文。
**Background of ELOA Antibody**
The ELOA (Elongin A) antibody targets the Elongin A protein, a critical component of the RNA polymerase II transcription elongation complex. Elongin A, encoded by the *ELOA* gene, functions as a transcriptional regulator by enhancing the elongation efficiency of RNA polymerase II, particularly under stress conditions. It forms a heterotrimeric complex with Elongin B and Elongin C, which stabilizes the interaction and facilitates recruitment to sites of DNA damage or paused transcription machinery.
ELOA is also a subunit of the multi-protein CRL (Cullin-RING ubiquitin ligase) complexes, contributing to ubiquitination processes that regulate protein degradation. Dysregulation of Elongin A has been implicated in cancer, neurodegenerative diseases, and autoimmune disorders, making it a focus for therapeutic and diagnostic research. For instance, its interaction with the von Hippel-Lindau (VHL) tumor suppressor protein links it to hypoxia response pathways and renal cell carcinoma pathogenesis.
Antibodies against ELOA are essential tools in studying transcriptional regulation, DNA repair mechanisms, and disease biomarkers. They are widely used in techniques like immunoprecipitation, Western blotting, and immunohistochemistry to explore Elongin A's expression, localization, and interactions in cellular models or clinical samples. Research on ELOA antibodies continues to advance understanding of gene expression control and potential therapeutic targets in oncology and beyond.
×
